{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:27Z","timestamp":1790351427050,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"crossref","award":["DGRC 2362\/07"],"award-info":[{"award-number":["DGRC 2362\/07"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003407","name":"MIUR","doi-asserted-by":"crossref","award":["PS 35-126\/Ind"],"award-info":[{"award-number":["PS 35-126\/Ind"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.leukres.2013.11.006","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T17:48:21Z","timestamp":1384537701000},"page":"236-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia"],"prefix":"10.1016","volume":"38","author":[{"given":"Concetta","family":"Quintarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santa","family":"Errichiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Colavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Raia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Risitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.11.006_bib0005","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","author":"Deininger","year":"2009","journal-title":"Blood"},{"issue":"February (5)","key":"10.1016\/j.leukres.2013.11.006_bib0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"January (4)","key":"10.1016\/j.leukres.2013.11.006_bib0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"September (13)","key":"10.1016\/j.leukres.2013.11.006_bib0020","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"issue":"November (11)","key":"10.1016\/j.leukres.2013.11.006_bib0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"February (6)","key":"10.1016\/j.leukres.2013.11.006_bib0030","first-page":"1501","article-title":"Chronic myeloid leukemia stem cells are not dependent on BCR-ABL kinase activity for their survival","volume":"119","author":"Hamilton","year":"2011","journal-title":"Blood"},{"issue":"September (13)","key":"10.1016\/j.leukres.2013.11.006_bib0035","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2011-03-341073","article-title":"SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia","volume":"118","author":"Esposito","year":"2011","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.leukres.2013.11.006_bib0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"August (13)","key":"10.1016\/j.leukres.2013.11.006_bib0045","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/pmic.201200444","article-title":"Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells","volume":"16","author":"Colavita","year":"2013","journal-title":"Proteomics"},{"issue":"July (1)","key":"10.1016\/j.leukres.2013.11.006_bib0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of BCR-ABL","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"issue":"March (10)","key":"10.1016\/j.leukres.2013.11.006_bib0055","first-page":"1824","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"September (10)","key":"10.1016\/j.leukres.2013.11.006_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2012.08.006","article-title":"Selective elimination of leukemia stem cells: hitting a moving target","volume":"1","author":"Crews","year":"2013","journal-title":"Cancer Lett"},{"issue":"December (12)","key":"10.1016\/j.leukres.2013.11.006_bib0065","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2009.175","article-title":"Contribution of bone microenvironment to leukemogenesis and leukemia progression","volume":"23","author":"Ayala","year":"2009","journal-title":"Leukemia"},{"issue":"October (10)","key":"10.1016\/j.leukres.2013.11.006_bib0070","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"June (6)","key":"10.1016\/j.leukres.2013.11.006_bib0075","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","article-title":"Potentiation of nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML","volume":"36","author":"Nair","year":"2012","journal-title":"Leuk Res"},{"issue":"May (5)","key":"10.1016\/j.leukres.2013.11.006_bib0080","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"issue":"September (5)","key":"10.1016\/j.leukres.2013.11.006_bib0085","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"issue":"August (6)","key":"10.1016\/j.leukres.2013.11.006_bib0090","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.leukres.2013.11.006_bib0095","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2403683","article-title":"Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia","volume":"19","author":"Pane","year":"2005","journal-title":"Leukemia"},{"issue":"January (1)","key":"10.1016\/j.leukres.2013.11.006_bib0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2013.11.006_bib0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","article-title":"Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring BCR-ABL kinase domain mutations: how reliable is the IC(5)(0)?","volume":"16","author":"Soverini","year":"2011","journal-title":"Oncologist"},{"issue":"March (12)","key":"10.1016\/j.leukres.2013.11.006_bib0110","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"issue":"July (7)","key":"10.1016\/j.leukres.2013.11.006_bib0115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic drug combinations tend to improve therapeutically relevant selectivity","volume":"27","author":"Lehar","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.leukres.2013.11.006_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"January (2)","key":"10.1016\/j.leukres.2013.11.006_bib0125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"June (24)","key":"10.1016\/j.leukres.2013.11.006_bib0130","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"October (10)","key":"10.1016\/j.leukres.2013.11.006_bib0135","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"November (20)","key":"10.1016\/j.leukres.2013.11.006_bib0140","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"November (11)","key":"10.1016\/j.leukres.2013.11.006_bib0145","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"October (28)","key":"10.1016\/j.leukres.2013.11.006_bib0150","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"January (3)","key":"10.1016\/j.leukres.2013.11.006_bib0155","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613003949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T02:06:31Z","timestamp":1596852391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613003949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0145212613003949"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}